We recently researched NIB Holdings (ASX:NHF) in The Dynamic Investor following recent company announcements and evolving trends in the private health sector. We observed that slowing policyholder growth, increasing competitive intensity and persistent claims inflation are expected to constrain margin expansion. However, potential capital management initiatives following the sale of its travel insurance operations may provide an offset.
With the shares currently trading at a discount to its recent average, we assess whether, on balance, NHF presents value at current levels.
About NIB Holdings
NIB Holdings is a provider of private health insurance in Australia and NZ and is also a provider of travel insurance and health insurance for inbound international students. The main earnings driver for NHF is the domestic business, Australian Residents Health Insurance (ARHI). The Company’s main competitor in the Australian Private Health Insurance (PHI) industry is ASX-listed company Medibank Private (ASX: MPL).
Key Fundamental Drivers
Policyholder Growth Rates Expected to Slow
For the six months to 31 December 2025 (1H26), policyholder growth for ARHI was +2.2%, which was below consensus estimates for +2.6% growth. The key contributing factors included an elevated lapse rate, with the Company noting competitive market dynamics.
At the 1H26 results release, the Company softened policyholder growth guidance for FY26, targeting above-system (i.e. industry) growth, versus prior guidance of around +3%. According to statistics reported by APRA, industry policyholder growth was ~+2.2% for the 12 months to 31 March 2026, with expectations amongst the major health insurers for the industry to achieve ~+1.9% policyholder growth this calendar year.
A key factor impacting the rate of industry policyholder growth is that promotional activity is intensifying across multiple large players – and is at the highest level seen over the last four years. Historically, health insurers have lifted their offerings around the peak churn period of April to June. Promotional activity was unusually high for the duration of calendar year 2025, with the first half of calendar year 2026 higher again.
Downside Risk to Net Margin
For 1H26, net margin for ARHI contracted around -20 basis points (bps) to 6.8%, reflecting mainly claims inflation of 5.3% over the previous year. While NHF expects to sustain net margins in 2H26, pressures are increasing for FY27, particularly from policy downgrading, which has increased to -1.5%. Even after the 5.5% premium increase effective from April 2026, persistent downgrading at this level implies claims inflation would need to moderate to around 4% per annum to maintain gross margins. This compares with claims inflation of around 8% in 1H26.
Claims growth during 2H26 has remained volatile, creating downside risk to FY26 net margin guidance of 6-7%. While claims in May were stable, claims in March and April were elevated due to hospitals bringing forward billing into December that has not yet normalised. Claims inflation per person on a rolling 12-month basis increased to 4.4% from 4.2% at December 2025, while affordability pressures continued to drive elevated switching and policy downgrading.
These trends are broadly consistent with industry conditions. PHI industry net margins declined to 3.6% in the March 2026 quarter (March 2025: 5.5%), reflecting higher claims costs and the normalisation of the unusually strong profitability recorded in FY25.
While APRA data indicate that hospital claims (around 70% of total benefits paid) moderated from the exceptionally strong December 2025 quarter, underlying claims costs remain elevated. This is driven by structural medical cost inflation, including higher private hospital payments from wage and operating cost increases, negotiated contract price rises, and higher specialist and prostheses costs.
Sale of Travel Insurance Operations Paves Way for Potential Capital Return
Following completion of the sale of its travel insurance operations in June 2026, NHF will undertake a capital management review to determine the best use of the sale proceeds. With proceeds of up to $117.5m expected from the sale of the three travel brands and ample franking credits ($194.5m as at 30 June 2025), there is potential for a capital return. To this end, the Company is likely to prioritise a fully franked special dividend over other forms of capital return.
Prior to the receipt of these proceeds, the Company already held excess capital. As at 31 December 2025, NHF’s Prescribed Capital Amount (PCA) ratio of 1.91x was above the minimum target of 1.5-1.6x for its ARHI division. This equated to an excess of ~$80-110m (16-23 cents per share) prior to the receipt of sale proceeds.
Fundamental View
Currently trading on a 1-year forward P/E multiple of ~16x, NHF shares are at a discount to the average over the last five years of ~17.5x as well as its higher-quality peer MPL (~21x). However, we contend that a cautious view is warranted given: i) The prospect of NHF’s ARHI policyholder growth being largely in line with the industry and ii) Net margin risk being skewed to the downside.
Charting View
NHF has shown little progress in the past 5 years and the price swings have been fairly large. It has had a good run in the past few months but it is now hitting a resistance zone. NHF is likely to experience some short-term resistance and head back to the mid $6’s which will give investors a better entry point.
Michael Gable is managing director of Fairmont Equities.
CLICK HERE to read our Testimonials.
Current share prices available here.
You can learn more about technical analysis in this article.
An 8-week FREE TRIAL to The Dynamic Investor can be found HERE.
Would you like us to call you when we have a recommendation? Check out our services.
Disclaimer: The information in this article is general advice only. Read our full disclaimer HERE.
Like this article? Share it now on Facebook and X!